Kornimate/medical-research-clean huggingface dataset:
balance systems protocol for subacute phase stroke patients.

Conditions: Stroke Sequelae

Summary: the aim of the study is to evaluate if the application of a protocol focused on the equilibrium systems versus the conventional treatments decreases the time to acquire equilibrium in standing, the risk of falls and favors the early initiation of treatments aimed at recovering the physiological gait.

in order to respond to the objectives, a randomized clinical trial was proposed on a total n of 70 stroke survivors (n = 35 patients in the control group and n = 35 patients in the intervention group), who are in the subacute stage of the disease, meet the inclusion and exclusion criteria, and require hospitalization to perform the rehabilitative treatment. for this, a rehabilitation treatment protocol was designed focusing on the equilibrium systems. the intervention of the study will be carried out during 4 weeks. the control group will receive conventional rehabilitation treatment for stroke patients, consisting of physiotherapy therapy for 60 minutes; while the intervention group will receive conventional rehabilitative treatment during the first 45 minutes and the last 15 minutes therapy will be based on the protocol designed. the evaluation of the program will be carried out based on the stated objectives. in order to evaluate the improvement of the patients in terms of balance, gait, risk of falls and patient autonomy, these will be assessed at the beginning of the intervention at 15 days and at the end (30 days). after the intervention two more assessments will be made; at 3 months and at 6 months to follow up in time.

Eligibility criteria:
inclusion criteria: * patients ≥ 18 years, who are admitted to an intermediate care unit after an acute stroke, for functional recovery. * diagnosis of ischemic or hemorrhagic stroke confirmed by magnetic resonance imaging (mri) or computed tomography (ct) scan. * patients with no alteration on sitting balance: patients should be able to sit on the edge of the bed with the hip and knees on 90º flexion, feet flat on the floor and inclination forward 30º towards the healthy and paretic side and able to return to the vertical balance without any support of the back or upper limbs. exclusion criteria: * patients with severe prior functional dependence (barthel index ≤60) * patients diagnosed with dementia or previous cognitive impairment * patients diagnosed with delirium. * patients diagnosed with wernicke aphasia. * patients with previous visual deficit (retinopathy, cataract, etc.) * patient with a history of other causes of balance impairment. * patients with orthopedic conditions that difficult the performance of the proposed rehabilitation treatment.

Keywords: stroke balance rehabilitation physiotherapy
local radiotherapy for residual tumor lesions during the first-line treatment

Conditions: Non Small Cell Lung Cancer

Summary: this study aimed to confirmed that local radiotherapy for residual lesions can significantly prolong the efficacy of chemotherapy combined with immunotherapy in the initial treatment of advanced non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * ≥18，advanced non-small cell lung cancer confirmed by histopathology patients received platinum-based chemotherapy combined with immunotherapy exclusion criteria: * egfr/alk/ros1 driver gene mutation * chemotherapy only * concurrent radio-chemotherapy * surgery * single-agent immunotherapy * no treatment information available
effectiveness of recruitment maneuvers and lung protective ventilation strategy in ards

Conditions: ARDS

Summary: the study was designed to comparison the effectiveness of recruitment maneuvers(rm) and lung protective ventilation strategy(lpvs) for patients with moderate to severe ards. ards patients were randomly divided into two groups, the experimental group (lpvs+rm group) and the control group (lpvs group). the method of rm refers to that under fio2=100% oxygen concentration and fixed inspiratory pressure (15cmh2o), the peep starts from 10 cmh2o and increases at a pressure of 5 cmh2o every minute until the peak inspiratory pressure(pip) reaches 55cmh2o, and the arterial blood oxygen is monitored at the same time. the pressure point when the partial pressure of arterial oxygen pao2+paco2≧400mmhg is the best peep. the primary endpoint indicators were oxygenation index(oi) and lung ultrasound score(lus) from day 1 to day 7. the secondary outcome indicators were the ventilator days, length of stay in the icu (days), and icu mortality.

ards patients were randomly divided into two groups, the experimental group (lpvs+rm group) and the control group (lpvs group). the method of rm refers to that under fio2=100% oxygen concentration and fixed inspiratory pressure (15cmh2o), the peep starts from 10 cmh2o and increases at a pressure of 5 cmh2o every minute until the peak inspiratory pressure(pip) reaches 55cmh2o, and the arterial blood oxygen is monitored at the same time. the pressure point when the partial pressure of arterial oxygen pao2+paco2≧400mmhg is the best peep. the primary endpoint indicators were oxygenation index(oi) and lung ultrasound score(lus) from day 1 to day 7. the secondary outcome indicators were the ventilator days, length of stay in the icu (days), and icu mortality.

Eligibility criteria:
inclusion criteria: * age 20 to 70 years old. * patients with hypoxemia receiving endotracheal mechanical ventilation therapy. * the ards diagnostic criteria of berlin definition, arterial oxygen tension \[pao2\]/fractional inspired oxygen \[fio2\] ratio (pao2/fio2) \<200 mm hg, recent appearance of bilateral pulmonary infiltrates consistent with edema and no clinical evidence of left atrial hypertension. * within 72 hours after ards diagnosis. exclusion criteria: * pregnancy. * participate in other interventional trials at the same time during the acceptance period. * severe trauma combined with rib fracture or pneumothorax, subcutaneous emphysema, and mediastinal air accumulation within three months. * severe chronic respiratory diseases that require long-term use of oxygen therapy or home mechanical ventilation. * have a history of cachexia or terminal cancer. * use immunosuppressants, chemotherapy or radiation therapy. * contraindications for hypercapnia, such as patients with acute brain injury due to intracranial hypertension or craniotomy.

Keywords: acute respiratory distress syndrome (ards) recruitment maneuvers (rm) oxygenation index(oi) lung ultrasound score(lus)
study of cs-3150 in patients with severe hypertension

Conditions: Severe Hypertension

Summary: to examine antihypertensive effect and safety of administration of cs-3150 in patients with severe hypertension (grade iii).


Eligibility criteria:
inclusion criteria: * male and female subjects aged 20 to 80 years at informed consent * subjects with severe hypertension, who do not receive any antihypertensive drugs or receive antihypertensive drug (except for potassium-sparing diuretics) during run-in period (sitting sbp ≥ 180 mmhg or sitting dbp ≥ 110 mmhg) exclusion criteria: * patients who are suspected hypertensive emergency * secondary hypertension or malignant hypertension * diabetes mellitus with albuminuria * serum potassium level \< 3.5 or ≥ 5.1 meq/l (≥ 4.8 meq/l if receive ra inhibitor) * egfr \< 60 ml/min/1.73 m\^2.

Keywords: severe hypertension grade iii hypertension mineralocorticoid receptor antagonist
a study to evaluate the pharmacokinetics and the safety after administration of br1015 and co-administration of br1015-3 and br1015-2 under fasting conditions

Conditions: Essential Hypertension

Summary: the purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of br1015 and co-administration of br1015-3 and br1015-2 in healthy volunteers under fasting conditions


Eligibility criteria:
inclusion criteria: * those weigh 50 kg or more and have body mass index (bmi) within the range of 18.0 to 30.0kg/m2 at screening visit. * those who sign written consent spontaneously after listening to and understanding sufficient explanation of the purpose and contents of this clinical trial, characteristics of the investigational products, expected adverse events, etc. * those who agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using methods of contraception accepted in clinical trial\*(except for hormone drugs) from the date of consent to 14 days after the last administration and disagrees to provide their sperm or ovum. * methods of contraception accepted in clinical trial: combined use of non hormonal intrauterine device, vasectomy, tubal ligation, and barrier methods (male condom, female condom, cervical cap, contraceptive diaphragm, sponge, etc.) or combined use of two or more barrier methods if spermicide is used. exclusion criteria: * those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 30 days prior to the first day of administration or have taken drugs concerned about affecting this clinical trial within 10 days prior to the first day of administration. (however, participation is possible considering pharmacokinetics and pharmacodynamics such as interaction of investigational products, half-life of concomitant drugs, etc.) * those who have participated in other clinical trials(including bioequivalence tests) and administered their investigational products within 6 months prior to the first administration date.(however, the termination for participation in other clinical trials are based on the last administration date of their investigational products) * those who have a medical history of gastrointestinal resection or gastrointestinal diseases that may affect the absorption of drugs. (except for simple appendectomy, hernia surgery) * those who can't discontinue a diet (ex. raw grapefruit, grapefruit juice or food containing grapefruit, etc.) that may affect the absorption, distribution, metabolism, and excretion of the drug within 48 hours prior to the first day of administration. * in the case of a female subject, those suspected pregnancy, pregnant woman, lactating woman.
oral misoprostol before endometrial biopsy

Conditions: Endometrial Biopsy

Summary: an endometrial biopsy involves a thin tube being passed through the cervix (opening of the uterus) to obtain a sample of the lining of the uterus. sometimes there may be discomfort with this procedure especially if the cervix is not dilated or opened. previous research has suggested that taking a drug called misoprostol may help the cervix to start to dilate or open. this study will see if misoprostol will help open the cervix for an endometrial biopsy, to lessen the discomfort and make the biopsy easier to perform.


Eligibility criteria:
inclusion criteria: * women 19 years and older * planned endometrial biopsy exclusion criteria: * known hypersensitivity or allery to prostaglandins * seizure disorder * liver disease * known abnormal liver function tests * pregnancy

Keywords: pain/discomfort cervical dilatation side effects
clinical risk score predicting the cardiac rupture in patients with st-elevation myocardial infarction

Conditions: Cardiac Rupture

Summary: the purpose of this study is to validate a practical risk score to predict the mechanical complication of st-elevation myocardial infarction (stemi).

stemi patients chewed 300 mg aspirin and 600 mg clopidogrel in the emergency department, followed by oral 100 mg aspirin and 75mg clopidogrel daily for at least 12 months. stemi patients received low molecular weight heparin (lmwh), β-blockers, and angiotensin converting enzyme inhibitors (acei) or angiotensin receptor blockers (arb) according to the stemi guideline, unless there were contraindications to these drugs. peripheral blood samples were collected from patients within 2 hours of admission for blood routines and blood biochemistry examinations. white blood cell counts and level of hemoglobin were assessed with automated cell counters via standard techniques. the investigators followed up patients in validation group for three month to observe the cardiac rupture events and other adverse cardiac events .

Eligibility criteria:
inclusion criteria: st-elevation myocardial infarction: concurrence of symptoms (chest pain or symptoms compatible with acute heart failure or unexplained syncope) and electrocardiogram findings (new onset left bundle branch block or st-segment elevation≥1 mm in ≥2 inferior leads or ≥2 mm in ≥2 precordial leads) exclusion criteria: cancer mental illness

Keywords: st-elevation myocardial infarction cardiac rupture risk assessment
study of levalbuterol and racemic albuterol in pediatric subjects with reactive airways disease (rad)

Conditions: Reactive Airways Disease (RAD)

Summary: the purpose of this study is to compare the efficacy of two dose levels of levalbuterol compared with one dose level of racemic albuterol in pediatric subjects aged birth to 48 months old.

a double-blind, randomized, active-controlled, multicenter, parallel-group trial of levalbuterol in pediatric subjects presenting with acute reactive airways disease. this study was previously posted by sepracor inc. in october 2009, sepracor inc. was acquired by dainippon sumitomo pharma., and in october 2010, sepracor inc's name was changed to sunovion pharmaceuticals inc.

Eligibility criteria:
inclusion criteria: * subject, male or female, must be between the ages of birth to 48 months inclusive at the time of consent. * subject must have experienced at least one previous episode or have a history of reactive airways disease. * subject must have an oxygen saturation ≥ 90% at room air or with no more than 2 l/min supplemental oxygen. exclusion criteria: * subject who has participated in an investigational drug study within 30 days prior to study start, or who has previously participated in this study. * subject with a known sensitivity to levalbuterol or racemic albuterol, including ventolin® or any of the excipients contained in any of these formulations. * subject using any prescription drug with which levalbuterol or racemic albuterol sulfate administration is contraindicated.

Keywords: rad reactive airways disease levalbuterol racemic albuterol
efficacy of deutetrabenazine to control symptoms of dysphagia associated with hd

Conditions: Huntington Disease

Summary: to determine the efficacy of deutetrabenazine to control symptoms of dysphagia associated with hd.

the primary endpoint is the change in swallow function/dysphagia from baseline to maintenance therapy.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of hd * symptoms of dysphagia * must be able to swallow tablets exclusion criteria: * other confounding diseases that affect swallowing * depression * hepatic impairment * renal impairment * dementia
comparison of a short uncemented femoral stem to a similar standard uncemented femoral stem

Conditions: Osteoarthritis, Hip

Summary: this randomized controlled trial will compare patients receiving a standard uncemented femoral stem with patients receiving an identically designed short uncemented femoral stem.

this randomized controlled trial will compare patients receiving a standard uncemented femoral stem with patients receiving an identically designed short uncemented femoral stem. patients will be randomized a few days before the operation. at the time of surgery, the surgeon will use the relevant implant. patients will be followed up for 5 years after surgery. the main outcome criteria is the stem subsidence measured radiographically with a dedicated software.

Eligibility criteria:
inclusion criteria: * hip osteoarthritis requiring a total hip replacement * \>18 years old * agrees to participate exclusion criteria: * total hip replacement not indicated * general anesthesia contraindicated * previous surgery on the ipsilateral femur * follow-up not possible
perfusion index-derived parameters as predictors post-induction hypotension.

Conditions: Hypotension; General Anesthesia Induced Hypotension

Summary: the perfusion index (pi) is a numerical value for the ratio between pulsatile and non-pulsatile blood flow measured by a special pulse oximeter. pi represents the baseline sympathetic tone which is assumed one of the factors contributing for hypotension. patients with low pi were reported by mahendale and rajasekhar to show greater hypotension after induction of anesthesia. this was explained by the high sympathetic tone in these patients which is suddenly masked by propofol administration leading to profound hypotension. this study aims to evaluate the ability of preoperative plethysmographic variability index, perfusion index and the dicrotic plethysmography to predict post-induction hypotension.

the perfusion index (pi) is a numerical value for the ratio between pulsatile and non-pulsatile blood flow measured by a special pulse oximeter. pi represents the baseline sympathetic tone which is assumed one of the factors contributing for hypotension. patients with low pi were reported by mahendale and rajasekhar to show greater hypotension after induction of anesthesia. this was explained by the high sympathetic tone in these patients which is suddenly masked by propofol administration leading to profound hypotension. moreover, the pi has been described as a reliable tool for vascular tone assessment and monitoring. dicrotic plethysmography (dicpleth): is easily derived from the photoplethysmographic signal. it represents the relative height of the dicrotic wave compared with the maximum peak of the waveform, has been described as the amount of reflected wave, dependent on the vascular tone. m.coutrot et al quantified dicpleth variations to detect arterial hypotension and mentioned that dicpleth and pi are both related to vascular tone and are easily derived from the photoplethysmographic signal. moreover, chowienczyk pj et. al. demonstrated that the reduction in dicpleth is related to the reduction of vascular tone caused by vasodilator drugs, such as salbutamol or glyceryl trinitrate

Eligibility criteria:
inclusion criteria: * • adult patients (18-59 years) * asa i-ii * patients scheduled for elective surgeries under general anaesthesia exclusion criteria: * • operations which will last for less than 15 minutes. * patients with cardiac morbidities (impaired contractility with ejection fraction \< 40% and tight valvular lesions, unstable angina). * patients with heart block and arrhythmia (atrial fibrillation and frequent ventricular or supraventricular premature beat). * patient with decompansted respiratory disease (poor functional capacity, generalized wheezes, peripheral o2 saturation \< 90% on room air). * patients with peripheral vascular disease or long standing dm affecting pvi readings. * pregnancy.
study of tazemetostat in participants with relapsed or refractory b-cell non-hodgkin's lymphoma with ezh2 gene mutation

Conditions: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Summary: this is a multicenter, open-label, phase 2 study to assess the efficacy and safety of tazemetostat in participants with relapsed or refractory b-cell non-hodgkin's lymphoma (nhl) with ezh2 gene mutation.


Eligibility criteria:
inclusion criteria: * participants with histological diagnosis of b-cell non-hodgkin's lymphoma (nhl) as follows: * cohort 1: follicular lymphoma (fl) * cohort 2: diffuse large b-cell lymphoma (including primary mediastinal b-cell lymphoma and transformed fl) * participants who have confirmed ezh2 gene mutation of tumor in central laboratory * participants who have measurable disease * participants who had previous therapy with systemic chemotherapy and/or antibody therapy and for which no standard therapy exists * participants who had progressive disease or did not have response (complete response or partial response) in previous systemic therapy, or relapsed or progressed after previous systemic therapy * participants with eastern cooperative oncology group performance status of 0 to 1 * participants with life expectancy of ≥3 months from starting study drug administration * participants with adequate renal, liver, and bone marrow function * male and female participants ≥20 years of age at the time of informed consent * participants who has provided written consent to participate in the study exclusion criteria: * participants with prior exposure to ezh2 inhibitor * participants with a history or a presence of central nerves invasion * participants with malignant pleural effusion, cardiac effusion, or ascites retention * participants with allogeneic stem cell transplantation * participants with medical need for the continued use of potent inhibitors of cytochrome p450 3a (cyp3a)or potent inducer of cyp3a (including st. john's wort) * participants with significant cardiovascular impairment · participants with prolongation of corrected qt interval using fridericia's formula to \> 480 milliseconds (msec) * participants with venous thrombosis or pulmonary embolism within the last 3 months before starting study drug * participants with complications of hepatic cirrhosis, interstitial pneumonia or pulmonary fibrosis * participants with active infection requiring systemic therapy * women of childbearing potential or man of impregnate potential who don't agree that both the participant and his/her partner will use a medically effective method for contraception for periods from before informed consent to during the clinical study and 30 days later (for males 90 days later) from last administration of study drug * woman who are pregnant or breastfeeding * participants who were deemed as inappropriate to participate in the study by the investigator or sub-investigator * have any prior history of t-cell lymphoblastic lymphoma/t-cell acute lymphoblastic leukemia or myeloid malignancies, including myelodysplastic syndrome

Keywords: ezh2 gene mutation tazemetostat diffuse large b-cell lymphoma follicular lymphoma
registry for pulmonary hypertension due to left heart disease in china

Conditions: Pulmonary Hypertension Due to Left Heart Disease

Summary: left heart disease is the main cause of pulmonary hypertension. with the advent of the aging society, chronic heart failure has become a global public health problem. therefore the prevalence of pulmonary hypertension due to the left heart disease is increasing. however, there is no research on the prevalence of pulmonary hypertension due to the left heart disease in china. therefore, the aim of the present study was to describe real-world outcome of chinese patients with pulmonary hypertension due to the left heart disease and identify factors that may predict outcome. our study will profile the demographics, clinical course, treatments, and outcomes of pulmonary hypertension due to the left heart disease in china.


Eligibility criteria:
inclusion criteria: * pulmonary hypertension due to left heart disease exclusion criteria: * other forms of pulmonary hypertension * heart failure due to valvular heart disease * hypertrophic obstructive cardiomyopathy * right ventricular outflow tract stenosis * pericardial disease * patients with chronic lung disease

Keywords: pulmonary hypertension left heart disease heart failure registry china